Article
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology - 1 Feb 2013
Tibes Raoul, Fine Gil, Choy Gavin, Redkar Sanjeev, Taverna Pietro, Oganesian Aram, Sahai Amarpal, Azab Mohammad, Tolcher Anthony W
Abstract excerpt
PURPOSE: Amuvatinib is a novel orally administered tyrosine kinase inhibitor with in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51. Amuvatinib was investigated in a first-in-human, single-agent, phase I, accelerated titration, dose-escalation trial ( clinicaltrials.gov identifier: NCT00894894) in patients with solid tumors refractory to prior...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.